Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, uncontrolled, open-label trial to evaluate the safety of extended treatment with brexpiprazole (OPC-34712) in patients with agitation associated with dementia of the Alzheimer's type

Next Previous
Trial Profile

A multicenter, uncontrolled, open-label trial to evaluate the safety of extended treatment with brexpiprazole (OPC-34712) in patients with agitation associated with dementia of the Alzheimer's type

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2018

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Agitation
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical

    • Most Recent Events

    • 02 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top